Figure 1From: Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer Immunohistochemical expression of CA9 (A to C) and VEGF (D to F) of strong (A and D), moderate (B and E), and weak (C and F) intensities.Back to article page